Entity

Time filter

Source Type

Waltham, MA, United States

Kornman K.S.,Interleukin Genetics | Polverini P.J.,University of Michigan
Clinical Genetics | Year: 2014

Dental care costs in the United States exceed $100 billion annually. Personalized medicine efforts in dentistry are driven by potentially compelling clinical utility and cost-effectiveness prospects in the major diseases of periodontitis, caries, and oral cancers. This review discusses progress and challenges identifying genetic markers and showing clinical utility in dentistry. Genome-wide association studies (GWAS) of chronic periodontitis (CP) identified no significant variants, but CDKN2BAS variants on chromosome 9 were significantly associated with aggressive periodontitis. Stratifying patients by interleukin (IL)-1 gene variants, smoking and diabetes differentiated CP prevention outcomes. Dental caries' GWAS identified significant signals in LYZL2, AJAp1, and KPNA4; and efforts are ongoing to identify genetic factors for multiple caries phenotypes. Trials of molecularly targeted therapies are in progress for oral, head, and neck squamous cell carcinomas (OHNSCC) and results have been promising but limited in their effectiveness. Current opportunities and challenges for molecular targeting for OHNSCC are discussed. © 2014 The Authors. Clinical Genetics published by John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.


An improved method and kit of determining whether a patient is predisposed to having severe periodontal disease and/or having high risk of progression of periodontal disease, comprising the steps of (i) taking a biological sample from said patient; (ii) genotyping said biological sample for genetic polymorphism pattern comprising IL 1B (rs16944), IL 1B (rs1143623) and IL 1B (rs4848306); and (iii) comparing said genetic polymorphism patterns to a reference composite genotype pattern; wherein the similarity of said genetic polymorphism patterns to said reference pattern indicate said patients predisposition to having severe periodontal disease and/or having high risk of progression of periodontal disease.


Patent
Interleukin Genetics and Tufts University | Date: 2010-07-09

Diagnostics and therapeutics for resistance to weight-loss, which are based upon the identification of a subjects PLIN polymorphisms, haplotype and genotype pattern, are described in this invention.


WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Friday, August 14, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s second quarter 2015 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com. The webcast will be archived following the call at www.ilgenetics.com. Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic risk panel for periodontal disease and tooth loss susceptibility available through dentists, and the Inherent Health® Weight Management Genetic Test that identifies the most effective diet program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA, and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Amendments (CLIA). For more information, please visit www.ilgenetics.com.


News Article | August 14, 2015
Site: www.businesswire.com

WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for its fiscal second quarter of 2015, ended June 30, 2015. “Interleukin Genetics is advancing on its mission to prevent and more cost-effectively manage chronic diseases,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics. “We have enhanced the positioning of PerioPredict®, our genetic test that identifies individuals with a life-long predisposition to produce inflammation, to target patients with chronic conditions such as diabetes and cardiovascular disease who will benefit from increased dental care. Engaging these high-risk Individuals provides significant leverage to improve wellness and lower costs, builds on the strong foundation of our relationships with collaborators and dental professionals, and is being well received by large employers and insurance carriers.” Mr. Carbeau continued, “Another key area where we see potential untapped value is expanding the application of our expertise in interleukin-1 genetics to collaborate with pharmaceutical firms to support the development of drug candidates that block interleukin-1, as we have done in the cardiovascular disease (CVD) area, and develop companion diagnostics for these drugs, and to introduce additional risk-based tests that would benefit physicians in the clinical management of their patients.” Total revenues for the second quarter ended June 30, 2015, were $376,000 compared to $529,000 for the same period in 2014. The change in total revenue is largely attributable to a decrease in the Company’s genetic test kits returned for processing related to the Company’s sales through Access Business Group’s promotional product bundle program. Research and development (R&D) expenses for the second quarter ended June 30, 2015, were $385,000 compared to $216,000 for the same period in 2014. The increase is primarily attributable to increased compensation due to annual salary increases for existing staff, and other expenses relating to Dr. Kornman moving back into R&D expenses from selling, general and administrative (SG&A) costs in April 2015. SG&A expenses for the second quarter ended June 30, 2015, were $1.7 million compared to $1.5 million for the same period in 2014. The increase is primarily attributable to expenses related to recruiting and hiring our new Chief Executive Officer and higher patent-related costs, partially offset by Dr. Kornman moving back into R&D. Net loss for the second quarter ended June 30, 2015, was $2.2 million or $(0.01) per basic and diluted common share compared to $1.6 million or $(0.01) per basic and diluted common share for the same period in 2014. Cash and cash equivalents at June 30, 2015, were $7.7 million, which management believes is sufficient to fund the Company’s operations for at least the next twelve months. Interleukin Genetics, Inc. will host a live conference call and webcast today at 8:30 a.m. EDT. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will be available and archived following the call at the Investors section of the Company’s website at www.ilgenetics.com. The PerioPredict® genetic test is quick, easy and painless and is performed under the direction of a dental professional during a routine exam or cleaning or as part of biometric screening. PerioPredict® measures variations in genes for Interleukin-1 (IL-1) to identify individuals with a life-long predisposition to overproduce inflammation to target patients with chronic conditions such as diabetes and cardiovascular disease who will benefit from increased dental care. PerioPredict® is run solely in the Interleukin Genetics CLIA-certified lab in Waltham, Mass. For more information, please visit www.PerioPredict.com. Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic risk panel for periodontal disease and tooth loss susceptibility available through dentists, and the Inherent Health® Weight Management Genetic Test that identifies the most effective diet program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA, and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Amendments (CLIA). For more information, please visit www.ilgenetics.com. Certain statements contained herein are “forward-looking” statements, including statements that there is potential value in expanding the application of the Company’s expertise in interleukin-1 genetics to collaborate with pharmaceutical firms to support the development of drug candidates that block interleukin-1, that the Company’s expanded activities with medical and dental carriers to initiate demonstration programs could lead to broader program adoption, that the Company’s genetic tests may provide physicians and pharmaceutical and medical device companies with novel genetic information to identify high-risk patients and develop personalized treatment options, and that cash and cash equivalents as of June 30, 2015, is sufficient to fund the Company’s operations for at least the next twelve months. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company’s annual report on Form 10-K for the year ended December 31, 2014, and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.

Discover hidden collaborations